Kevin Gorman, Neurocrine CEO
Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal
Eight months after Neurocrine $NBIX chronicled a flop for a mid-stage schizophrenia drug, the biotech is headed right back into Phase II armed with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
